| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Herpes Simplex Virus 1+2 reactive IgM |
| species reactivity | Herpes Simplex Virus |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available size | 3 mL |
Herpes Simplex Virus 1+2 IgM Control Serum BC105M
$94.00
Summary
- Virion/Serion Diagnostic Kit Control for research use (RUO)
- Herpes Simplex Virus (HSV) 1+2 IgM Control Serum
- Applications: ELISA
- IgM control serum
- Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
- 3 mL
Herpes Simplex Virus 1+2 IgM Control Serum BC105M
| target relevance |
|---|
| Organism Herpes Simplex Virus 1/2 |
| Protein names Herpes Simplex Virus (HSV) |
| Structure and strains Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known by their taxonomic names Human alphaherpesvirus 1 and Human alphaherpesvirus 2, are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Both HSV-1 and HSV-2 are very common and contagious. They can be spread when an infected person begins shedding the virus. As of 2016, about 67% of the world population under the age of 50 had HSV-1. In the United States, about 47.8% and 11.9% are estimated to have HSV-1 and HSV-2, respectively, though actual prevalence may be much higher. Because it can be transmitted through any intimate contact, it is one of the most common sexually transmitted infections. |
| Detection and diagnosis An important field of application for HSV serology - also during latency - is the detection of serotype-specific HSV IgG antibodies in order to identify potential HSV carriers who could infect susceptible individuals. In particular, the identification of HSV 2 serotype-specific antibodies in pregnant women, who present a high risk of transferring the virus to a newborn child, is recommended. The serological typing of an HSV infection is usually performed by identifying IgG antibodies directed against the viral surface glycoproteins G (gG) of HSV 1 (gG1) and HSV 2 (gG2). Due to the fact that these antibodies are only produced some weeks after a primary infection, the determination of serotype-specific antibodies can also assist in the differentiation between primary infection and reactivation |
Data
FAQ & Publications
Frequently Asked Questions
What is the intended application for the Herpes Simplex Virus 1+2 IgM Control Serum BC105M?
The Herpes Simplex Virus 1+2 IgM Control Serum BC105M is designed for use in ELISA assays as an IgM control serum for research purposes.
How should the Herpes Simplex Virus 1+2 IgM Control Serum BC105M be stored to maintain its stability?
This control serum should be stored at a temperature between 2-8°C to ensure optimal stability and performance.
Is the Herpes Simplex Virus 1+2 IgM Control Serum BC105M compatible with specific ELISA kits?
Yes, the serum is ready-to-use and pre-diluted specifically for compatibility with SERION ELISA classic and SERION ELISA antigen assays.
Which virus species does the Herpes Simplex Virus 1+2 IgM Control Serum BC105M target?
The control serum targets antibodies reactive to Herpes Simplex Virus types 1 and 2 (HSV-1 and HSV-2).
What is the volume of the Herpes Simplex Virus 1+2 IgM Control Serum BC105M provided in each vial?
Each vial contains 3 mL of the Herpes Simplex Virus 1+2 IgM Control Serum BC105M, supplied ready-to-use.
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Protocols
| relevant to this product |
|---|
| BC105M protocol |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.